Dr. Said Dermime, Ph.D.
Dr. Dermine is the director of Translational Cancer Research Facility, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar. Dr. Dermime has more than 24 years of experience in the field of Tumor Immunology. Dr. Dermime received his Ph.D. degree in Immunology from Salford University in Manchester, UK in 1992;then, he joined the National Cancer Institute of Milan, Italy for a period of 2 years as a postdoctoral fellow followed by 2 years as a researcher at NHLBI, NIH in Bethesda, USA under an NIH Fogarty International Award. Dr. Dermime then worked in PPL Therapeutics Limited, London, UK, and COBRA Therapeutics Ltd., UK, where he gained industrial experience. He was then appointed at the Paterson Institute for Cancer Research in Manchester, UK, as a lymphoma-cancer-vaccine team leader for 4 years. Subsequently, he established and led the Tumor Immunology Section at King Faisal Specialist Hospital & Research Centre in Riyadh, KSA, for a period of 6 years as a senior scientist. In 2008, he joined the Dasman Diabetes Institute in Kuwait to establish and lead the department of Biomedical Research and to head the Immunology & Innovative Cell Therapy Unit. Dr. Dermime is currently a member of several international scientific societies and is also an active member of the editorial board of various immunology journals and on the scientific boards of international organizations. He supervised several Ph.D. and master’s students and received several research grants from different organizations such as the Christie Hospital Endowment funds (United Kingdom), ASTF (United Arab Emirates), KACST (Saudi Arabia) and KFAS (Kuwait). Dr. Dermime published over 42 peer-reviewed articles in high-impact journals such as Blood, Journal of Immunology, Clinical Cancer Research, and Cancer Research.